(Q39990738)

English

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Yasushi Yatabe

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

author name string

Masayasu Hara

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Hayao Nakanishi

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Kunio Tsujimura

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Makoto Matsui

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Tadao Manabe

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Masae Tatematsu

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

16 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

1471-1478

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Current role of antibody therapy in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Comparing antibody and small-molecule therapies for cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)‐tagged human gastric cancer cell line

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Mixed gastric- and intestinal-type metaplasia is formed by cells with dual intestinal and gastric differentiation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Evaluation of chemosensitivity of micrometastases with green fluorescent protein gene-tagged tumor models in mice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Interaction of aggregated -globulin with B lymphocytes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Complement function in mAb-mediated cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00821.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2008.00821.X

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39990738&oldid=1882078520"